Table 2. Downregulated miRNAs in sunitinib-treated RCC (versus primary RCC).

miRNA	Log2 ratio (sunitinib failure/primary)	Primary RCC	Sunitinib failure RCC	P-value
hsa-miR-101	–9.89	0.00193	2.04E-06	6.74E-05
hsa-miR-29b	–9.73	0.00213	2.51E-06	6.20E-05
hsa-miR-190	–9.66	0.00061	7.51E-07	6.39E-04
hsa-miR-128	–9.46	0.00036	5.11E-07	2.52E-04
hsa-miR-23b	–9.40	0.00035	5.11E-07	2.80E-03
hsa-miR-10b	–9.36	0.00599	9.10E-06	3.84E-04
hsa-miR-766	–9.27	0.00032	5.11E-07	1.75E-03
hsa-miR-142-5p	–9.22	0.00035	5.92E-07	9.89E-04
hsa-miR-1275	–9.03	0.00027	5.11E-07	2.17E-03
hsa-miR-629	–8.99	0.00026	5.11E-07	3.24E-04
hsa-let-7c	–8.91	0.00216	4.49E-06	3.73E-04
hsa-miR-135a	–8.89	0.0006	1.26E-06	3.77E-02
hsa-miR-320b	–8.84	0.00083	1.81E-06	7.83E-05
hsa-miR-24-2*	–8.82	0.00023	5.11E-07	2.68E-04
hsa-miR-99a*	–8.67	0.00035	8.60E-07	2.96E-04
hsa-miR-31*	–8.59	0.00112	2.92E-06	4.68E-02
hsa-miR-450a	–8.57	0.00019	5.11E-07	1.33E-03
hsa-miR-455-3p	–8.49	0.00173	4.80E-06	5.45E-05
hsa-miR-340	–8.43	0.00448	1.30E-05	6.99E-08
hsa-miR-126*	–8.37	0.09059	2.75E-04	1.85E-04
hsa-miR-15b*	–8.35	0.00017	5.11E-07	8.21E-03
hsa-miR-29c	–8.32	0.03819	1.20E-04	1.13E-04
hsa-miR-204	–8.29	0.03376	1.08E-04	6.10E-03
hsa-miR-424*	–8.14	0.00014	5.11E-07	2.59E-03
hsa-miR-27b	–8.13	0.00574	2.05E-05	2.67E-04
hsa-miR-1	–8.08	0.00014	5.11E-07	5.84E-03
hsa-miR-592	–8.05	0.00111	4.19E-06	2.77E-03
hsa-miR-20a*	–7.97	0.0003	1.21E-06	4.21E-04
hsa-miR-450b-5p	–7.85	0.00024	1.02E-06	1.48E-05
hsa-miR-10a	–7.69	0.00458	2.22E-05	1.95E-04
hsa-let-7a	–7.64	0.00517	2.60E-05	3.20E-06
hsa-miR-32	–7.63	0.00014	7.23E-07	1.13E-04
hsa-miR-324-5p	–7.63	0.00079	3.98E-06	1.07E-04
hsa-miR-429	–7.63	0.0042	2.12E-05	5.17E-04
hsa-miR-98	–7.61	0.00055	2.80E-06	1.39E-06
hsa-miR-598	–7.59	0.00105	5.42E-06	5.39E-06
hsa-miR-148b	–7.57	0.00042	2.20E-06	8.74E-07
hsa-miR-577	–7.56	0.00021	1.11E-06	7.18E-03
hsa-miR-26b	–7.51	0.05631	3.10E-04	3.85E-06
hsa-miR-545	–7.48	0.00018	1.03E-06	3.89E-05